(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

• Published in: Cancer imaging Vol. 16; no. 1; p. 14
• Main Authors: Rauscher, Isabel, Maurer, Tobias, Fendler, Wolfgang P, Sommer, Wieland H, Schwaiger, Markus, Eiber, Matthias
• Format: Journal Article
• Language: English
• Published: England 08.06.2016
• Subjects: Edetic Acid - analogs & derivatives; Humans; Image Interpretation, Computer-Assisted - methods; Male; Medical Records; Oligopeptides; Positron Emission Tomography Computed Tomography - methods; Prostatic Neoplasms - diagnostic imaging; Radiopharmaceuticals; Positron emission tomography; Prostate cancer; Prostate specific membrane antigen
• ISSN: 1470-7330; 1470-7330
• DOI: 10.1186/s40644-016-0072-6

Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with (68)Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with (68)Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of (68)Ga-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine.